非神经性乙胆酶活性在早期检测败血症方面具有有限的实用性
Aleksandar R Zivkovic1, Karsten Schmidt2, Stefan Hofer3
1Department of Anesthesiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Biomedicines
|August 26, 2023
概括
乙胆酶 (AChE) 活性不能可靠地表明早期的败血症发作或预测患者的疾病严重程度. 测量结果最初显示AChE水平稳定,28天后下降,但与临床结果没有相关性.
科学领域:
- 生物化学 生物化学
- 关键护理医学 关键护理医学
- 免疫学 免疫学 免疫学
背景情况:
- 败血症是一种危及生命的全身性炎症反应.
- 胆固醇系统,包括乙胆酶 (AChE),在炎症中起作用.
- 非神经元ACHE作为早期败血症生物标志物的有用性是不确定的.
研究的目的:
- 调查ACHE活动在败血症中的作用.
- 评估AChE活动与败血症严重程度之间的相关性.
- 评估 AChE 活动与患者结局的关联.
主要方法:
- 对43名败血症患者进行前性研究.
- 测量AChE活动在败血症检测时,7天和28天.
- 评估炎症生物标志物,疾病严重程度得分和临床结果.
主要成果:
- 在检测后的7天内,ACHE活动保持稳定.
- 到28日,ACHE活动显著下降.
- 在最初的ACHE活性和炎症标志物,疾病严重程度或住院/ICU停留时间之间没有发现相关性.
结论:
- 非神经元AChE活动不是败血症的可靠早期指标.
- AChE活动似乎不能预测败血症疾病的严重程度或患者的结果.
相关概念视频
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Cholinesterases: Distribution and Function
502
Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
502
Anticholinesterase Agents: Poisoning and Treatment
920
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
920
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
715
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
715
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.3K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.3K
Myasthenia Gravis: Diagnostic Tests
1.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.0K


